

# Renovascular hypertension: the role of angioplasty after selecting patients according to the doppler resistive index

<b>Submission date</b> 26/09/2005	<b>Recruitment status</b> Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 26/09/2005	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 25/02/2009	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Gilles Soulez

**Contact details**  
CHUM-Notre-Dame  
Département de Radiology  
1560 rue Sherbrooke Est  
Montréal  
Canada  
H2L 4M1  
+1 514 890 8000 ext. 26522  
gilles.soulez.chum@ssss.gouv.qc.ca

## Additional identifiers

**Protocol serial number**  
MCT-52685

## Study information

**Scientific Title**

The role of angioplasty after selecting patients according to the doppler resistive index: a randomised controlled trial

### **Study objectives**

Medical treatment and renal angioplasty in renovascular hypertension

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Comite d'ethique de la recherche, Hopital Notre Dame, Centre Hospitalier de L'universite de Montreal (CHUM), Montreal, Québec approved on 14th May 2002.

### **Study design**

Randomised controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Renovascular hypertension

### **Interventions**

Added 25/02/2009: the study was terminated early due to recruitment issue.

Inclusion of patients presenting a controlled hypertension with 2 or 3 antihypertensive drugs and risk factors for renovascular hypertension. Selection on Doppler inclusion criteria (Resistive index less than 0.75) and renal angiography renal artery stenosis of more than 60% in diameter.

Group 1: Medical treatment (duration: 12 months)

Group 2: Renal angioplasty

Follow up for one year following angioplasty.

Trial details received: 12 Sept 2005

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome(s)**

Systolic and diastolic blood pressure 12 months post-randomisation

### **Key secondary outcome(s)**

1. Blood pressure at 1 and 6 months post-randomisation
2. Clinical success on blood pressure control at 12 months

3. Serum creatine clearance when off antihypertensive drugs during 12 months? Does it mean that you have no control over those?
4. Morbidity related to cardiovascular events during follow-up
5. Incidence of renal artery restenosis

**Completion date**

30/03/2006

**Reason abandoned (if study stopped)**

Participant recruitment issue

## Eligibility

**Key inclusion criteria**

1. Hypertension greater than 140/90 mmHg with two hypertensive drugs
2. Hypertension less than 140/90 mmHg with three antihypertensive drugs
3. Aged greater than or equal to 30 years old, either sex
4. Atherosclerotic renal artery stenosis of more than 60% on catheter angiography or 70% on computed tomography (CT) or magnetic resonance (MR) angiography
5. Doppler resistive index less than 0.75

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Creatinine clearance less than 30 ml/min
2. Non controlled hypertension (greater than 160/105 mmHg) despite 3 anti-hypertensive drugs
3. Renal artery stenosis greater than 95%
4. Fibromuscular dysplasia

**Date of first enrolment**

01/09/2002

**Date of final enrolment**

30/03/2006

## Locations

**Countries of recruitment**

Canada

**Study participating centre**  
**CHUM-Notre-Dame**  
Montréal  
Canada  
H2L 4M1

## Sponsor information

**Organisation**  
Hospital Notre-Dame (Montréal) (Canada)

**ROR**  
<https://ror.org/01w7qz648>

## Funder(s)

**Funder type**  
Research organisation

**Funder Name**  
Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr-irsc.gc.ca> (ref: MCT-52685)

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	cost-benefit analysis results	01/03/2005		Yes	No